Bachurski, P. (2026) “Optimal First-Line Use of Pembrolizumab in Metastatic Driver-Negative NSCLC: Monotherapy Versus Chemo-Immunotherapy (Evidence 2022–2025)”, Quality in Sport, 51, p. 68252. doi: 10.12775/QS.2026.51.68252.